BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18450388)

  • 1. [Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers].
    Drouet L
    Pathol Biol (Paris); 2008 Jun; 56(4):195-204. PubMed ID: 18450388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombosis in multiple myeloma.
    Zangari M; Elice F; Fink L; Tricot G
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):307-15. PubMed ID: 17338651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide and thrombosis. A meta-analysis.
    El Accaoui RN; Shamseddeen WA; Taher AT
    Thromb Haemost; 2007 Jun; 97(6):1031-6. PubMed ID: 17549307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic events in patients with cancer receiving antiangiogenesis agents.
    Zangari M; Fink LM; Elice F; Zhan F; Adcock DM; Tricot GJ
    J Clin Oncol; 2009 Oct; 27(29):4865-73. PubMed ID: 19704059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
    van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
    Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
    Musallam KM; Dahdaleh FS; Shamseddine AI; Taher AT
    Thromb Res; 2009 Mar; 123(5):679-86. PubMed ID: 18992924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
    Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
    Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
    Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
    Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drugs and venous thromboembolism].
    Lacut K; Mottier D; Pottier P
    Rev Pneumol Clin; 2008 Dec; 64(6):290-7. PubMed ID: 19084208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomid: current role in the treatment of non-plasma cell malignancies.
    Kumar S; Witzig TE; Rajkumar SV
    J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombosis associated with angiogenesis inhibitors.
    Elice F; Rodeghiero F; Falanga A; Rickles FR
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):115-28. PubMed ID: 19285278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide.
    Koh Y; Bang SM; Lee JH; Yoon HJ; Do YR; Ryoo HM; Lee N; Kim SJ; Kim K; Yoon SS; Won JH; Mun YC; Lee MH; Rhee KH; Kim HJ; Eom H; Kim MK; Shin HC;
    Ann Hematol; 2010 Feb; 89(2):201-6. PubMed ID: 19705118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
    Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects of thalidomide administration in patients with neoplastic diseases.
    Dimopoulos MA; Eleutherakis-Papaiakovou V
    Am J Med; 2004 Oct; 117(7):508-15. PubMed ID: 15464708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide-induced reversible interstitial pneumonitis in a patient with recurrent ovarian cancer.
    Buttin BM; Moore MJ
    Gynecol Oncol; 2008 Dec; 111(3):546-8. PubMed ID: 18191185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
    Uaprasert N; Voorhees PM; Mackman N; Key NS
    Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma.
    Singh A; Gajra A
    Cardiovasc Hematol Agents Med Chem; 2011 Jan; 9(1):7-13. PubMed ID: 20874693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma and treatment-related thromboembolism: oncology nurses' role in prevention, assessment, and diagnosis.
    Wiley KE
    Clin J Oncol Nurs; 2007 Dec; 11(6):847-51. PubMed ID: 18063543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thromboembolic events associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
    Rome S; Doss D; Miller K; Westphal J;
    Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):21-8. PubMed ID: 18490254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.